標題: Titlebook: Biologic Therapy of Leukemia; Matt Kalaycio Book 2003 Springer Science+Business Media New York 2003 antibody.cytokine.cytokines.dendritic [打印本頁] 作者: Blandishment 時間: 2025-3-21 16:11
書目名稱Biologic Therapy of Leukemia影響因子(影響力)
書目名稱Biologic Therapy of Leukemia影響因子(影響力)學科排名
書目名稱Biologic Therapy of Leukemia網(wǎng)絡公開度
書目名稱Biologic Therapy of Leukemia網(wǎng)絡公開度學科排名
書目名稱Biologic Therapy of Leukemia被引頻次
書目名稱Biologic Therapy of Leukemia被引頻次學科排名
書目名稱Biologic Therapy of Leukemia年度引用
書目名稱Biologic Therapy of Leukemia年度引用學科排名
書目名稱Biologic Therapy of Leukemia讀者反饋
書目名稱Biologic Therapy of Leukemia讀者反饋學科排名
作者: Thyroxine 時間: 2025-3-21 23:46
Radiolabeled Monoclonal Antibodies-mediated cytotoxicity (ADCC), in which an effector cell expressing an Fc receptor binds to a cell-bound MAb and is triggered to kill the target cell. Examples of antibodies with intrinsic immunologically mediated antitumor activity include the chimeric anti-CD20 antibody rituximab . and the humaniz作者: CLAN 時間: 2025-3-22 00:23 作者: 浮雕寶石 時間: 2025-3-22 07:33 作者: Oligarchy 時間: 2025-3-22 12:39 作者: Tartar 時間: 2025-3-22 13:21 作者: Gudgeon 時間: 2025-3-22 18:17 作者: gorgeous 時間: 2025-3-22 23:53
Franz J. Frei,Thomas Erb,Robert Sümpelmann in their eradication. The . Web site currently lists 596 clinical trials initiated since 1989, including 376 (63%) that are related to the treatment of malignancies, with 2389 patients enrolled in cancer-related gene therapy protocols .. A total of 46 (8%) of all gene therapy trials focus on the tr作者: leniency 時間: 2025-3-23 01:42
Human Leukemia-Derived Dendritic Cells as Tools for Therapy such as the recently developed tyrosine kinase inhibitor Imatinib Mesylate, may fail to control advanced forms of the target disease .. Additionally, for many human leukemias, no such well-defined genetic background is available at present. Accordingly, efforts to advance the therapy for these diseases must focus on other approaches.作者: fibroblast 時間: 2025-3-23 09:19
Interleukin-2 Treatment of Acute Leukemia(AML), 60–80% of patients will initially achieve complete remission (CR) but the majority of them will relapse .. Only 10%–30% of patients achieve prolonged leukemia-free survival .. In the case of acute lymphocytic leukemia (ALL), 60–65% of children can achieve long-term survival but only 10–30% of adults survive 5 yr free of recurrence ..作者: Isolate 時間: 2025-3-23 12:40 作者: 行業(yè) 時間: 2025-3-23 16:55
Book 2003ent place crucial information on the uses and limitations of the major biologic therapies for leukemia, the different biologic strategies for its treatment, the management of patients being treated with such biologic agents, and the current and future role of emerging biologic agents.作者: judicial 時間: 2025-3-23 21:31 作者: Extemporize 時間: 2025-3-23 23:21 作者: CHASE 時間: 2025-3-24 06:26
,An?sthesie bei Neu- und Frühgeborenen,ifying the biologic basis of leukemia, expecting that agents that more precisely target leukemia can be developed to maximize responses while minimizing toxicity. This approach requires the identification of appropriate targets, and the necessary tools to undertake this process have only recently become available.作者: 靦腆 時間: 2025-3-24 07:14
Book 2003out their use when making patient treatment decisions. Biologic Therapy of Leukemia summarizes and reviews all the available data concerning these cutting-edge biologic therapies so that practicing clinicians can make the correct patient-care choices. Here the busy physician will find in one conveni作者: chondromalacia 時間: 2025-3-24 12:40 作者: 重畫只能放棄 時間: 2025-3-24 16:29
Physiologie und Pathophysiologie,logy and antibodycalicheamicin conjugate pharmacology. Finally, we suggest strategies to reduce the normal tissue toxicities and broaden the clinical use of this new exciting therapy. Lessons learned with this agent may be useful in the development and application of future drug immunoconjugates.作者: 一大群 時間: 2025-3-24 20:24 作者: adipose-tissue 時間: 2025-3-25 01:06
Drug Immunoconjugate Therapy of Acute Myeloid Leukemialogy and antibodycalicheamicin conjugate pharmacology. Finally, we suggest strategies to reduce the normal tissue toxicities and broaden the clinical use of this new exciting therapy. Lessons learned with this agent may be useful in the development and application of future drug immunoconjugates.作者: Fibrinogen 時間: 2025-3-25 04:05
All-,-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemiaf ATRA and chemotherapy. ATRA syndrome remains the major combination of ATRA treatment, which should be prevented by addition of chemotherapy and/or dexamethasone in case of raising white blood cell (WBC) counts.作者: CANE 時間: 2025-3-25 10:19
it difficult to make informed decisions about their use when making patient treatment decisions. Biologic Therapy of Leukemia summarizes and reviews all the available data concerning these cutting-edge biologic therapies so that practicing clinicians can make the correct patient-care choices. Here 作者: 貧窮地活 時間: 2025-3-25 13:48
Franz J. Frei,Thomas Erb,Robert Sümpelmannrane-enclosed fragments, which are then engulfed by neighboring cells or professional phagocytes .. These biochemical changes are believed to reflect, at least in part, the action of caspases, unique intracellular proteases that digest critical polypeptides required for cellular integrity and survival ..作者: buoyant 時間: 2025-3-25 19:12
Franz J. Frei,Thomas Erb,Robert Sümpelmann century .. The fascination with arsenic was enhanced when Paul Ehrlich developed salvarsan, a formulation that contained organic arsenic used to treat syphilis .. However, clinicians’ interests in arsenic were abandoned as data accumulated on its toxic effects ..作者: aerial 時間: 2025-3-25 21:53
Targeting the Apoptotic Machinery as a Potential Antileukemic Strategyrane-enclosed fragments, which are then engulfed by neighboring cells or professional phagocytes .. These biochemical changes are believed to reflect, at least in part, the action of caspases, unique intracellular proteases that digest critical polypeptides required for cellular integrity and survival ..作者: Adulate 時間: 2025-3-26 02:54 作者: 組裝 時間: 2025-3-26 08:05
,An?sthesieger?te und Monitoring,votal clinical studies using IFN-α for treatment of chronic myelogenous leukemia (CML) were already published in 1983 by Talpaz et al. .. Further development of IFNs as antitumor agents developed rapidly, and today recombinant IFN-α is approved worldwide in more than 40 countries for treatment of various malignancies and viral diseases ..作者: 吵鬧 時間: 2025-3-26 10:53 作者: Simulate 時間: 2025-3-26 16:29
Physiologie und Pathophysiologie,olecular biology of leukemia has identified a series of target genes whose protein products are integral to the pathogenesis of leukemia. Much of this insight has initially been garnered from cytogenetic observations and clinical correlations. These sentinel discoveries have been bolstered by the availability of genomic and proteomic screening.作者: STELL 時間: 2025-3-26 18:07 作者: vanquish 時間: 2025-3-26 21:57 作者: 克制 時間: 2025-3-27 04:51 作者: Junction 時間: 2025-3-27 06:38 作者: Console 時間: 2025-3-27 11:40
,An?sthesieger?te und Monitoring,s later shown that they play an important role not only in antiviral control but also in cellular proliferation control and in immune system modulation. According to the cellular origin, IFNs can be classified as leukocyte, fibroblast, or immune IFN .. Leukocyte and fibroblast IFNs are also called t作者: cutlery 時間: 2025-3-27 16:42
Physiologie und Pathophysiologie,ion and dose-intensive consolidation. Long-term survival, however, remains elusive. Despite a better understanding of disease biology, including pretreatment characteristics and unique cytogenetic features, the prognosis for adult patients with acute leukemia remains poor. In acute myeloid leukemia 作者: 牲畜欄 時間: 2025-3-27 20:54 作者: 漂白 時間: 2025-3-27 23:19
,An?sthesie bei Neu- und Frühgeborenen, of leukemia was poorly understood. Although cytotoxic chemotherapeutic drugs have played and continue to play an essential role in cancer management, their relative lack of specificity, numerous toxicities, and frequency of resistance have limited this approach. Recent efforts have focused on ident作者: ALLAY 時間: 2025-3-28 02:38
Physiologie und Pathophysiologie,iated with a poor prognosis. In multiple clinical series, Pgp has been associated with a poor response to chemotherapy, early relapse, decreased remission duration, and shorter overall survival. Expression of Pgp is typically higher in patients with more advanced disease, such as those who have rela作者: 墻壁 時間: 2025-3-28 09:31 作者: 不可接觸 時間: 2025-3-28 10:43
Franz J. Frei,Thomas Erb,Robert Sümpelmannh century. The compound known as Fowler’s solution contained a potassium bicarbonate-based arsenic trioxide (ATO) that was in use until the early 20th century .. The fascination with arsenic was enhanced when Paul Ehrlich developed salvarsan, a formulation that contained organic arsenic used to trea作者: 預測 時間: 2025-3-28 17:22 作者: 剝皮 時間: 2025-3-28 20:06
Franz J. Frei,Thomas Erb,Robert Sümpelmann.. Gene therapy approaches can be divided into the manipulation of reproductive cells to maintain a genetic modification in future generations (germ-line gene therapy) or gene transfer into more differentiated tissues, such as cells of the lung, liver, or brain, or hematopoietic cells (somatic gene 作者: 赤字 時間: 2025-3-29 02:02
Antisense Therapyolecular biology of leukemia has identified a series of target genes whose protein products are integral to the pathogenesis of leukemia. Much of this insight has initially been garnered from cytogenetic observations and clinical correlations. These sentinel discoveries have been bolstered by the availability of genomic and proteomic screening.作者: 過多 時間: 2025-3-29 04:32
F. J. Frei,C. Jonmarker,O. WernerMonoclonal antibodies (MAbs) have been studied as a treatment for leukemia for approximately 20 years but have only recently been used successfully. The history of MAb development has been reviewed extensively .. The purpose of this chapter is to review the clinical data supporting the use of unconjugated MAbs in the treatment of leukemia.作者: STALL 時間: 2025-3-29 09:03
Unconjugated Monoclonal AntibodiesMonoclonal antibodies (MAbs) have been studied as a treatment for leukemia for approximately 20 years but have only recently been used successfully. The history of MAb development has been reviewed extensively .. The purpose of this chapter is to review the clinical data supporting the use of unconjugated MAbs in the treatment of leukemia.作者: precede 時間: 2025-3-29 14:50 作者: eardrum 時間: 2025-3-29 15:57 作者: 半身雕像 時間: 2025-3-29 19:46
Matt KalaycioIncludes supplementary material: 作者: 預知 時間: 2025-3-30 01:59 作者: hair-bulb 時間: 2025-3-30 04:32 作者: Constrain 時間: 2025-3-30 09:41
The Graft vs Leukemia Effecto deliver anticancer therapy (chemotherapy and/or radiation therapy) is limited by dose toxicities, primarily toxicity to normal bone marrow; tumors not susceptible to repetitive doses of modest amounts of chemotherapy might be completely obliterated with one extremely large dose of chemotherapy and作者: Freeze 時間: 2025-3-30 15:42 作者: voluble 時間: 2025-3-30 16:34 作者: 姑姑在炫耀 時間: 2025-3-30 23:37 作者: 才能 時間: 2025-3-31 01:46
Interleukin-2 Treatment of Acute Leukemiaion and dose-intensive consolidation. Long-term survival, however, remains elusive. Despite a better understanding of disease biology, including pretreatment characteristics and unique cytogenetic features, the prognosis for adult patients with acute leukemia remains poor. In acute myeloid leukemia 作者: 品牌 時間: 2025-3-31 07:10
